PHAR: SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for PHAR
Across the 29 sessions after earlier PHAR headlines, the stock closed higher 14 times and lower 14 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PHAR | SPY |
|---|---|---|---|
| Oct 22, 2026 | Pharming Group announces third quarter 2026 revenues above market expectations | +10.6% | -1.2% |
| Oct 14, 2026 | Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026 | +2.1% | -1.1% |
| Sep 29, 2026 | Pharming announces CEO transition | -4.8% | -0.2% |
| Sep 25, 2026 | Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS | +0.2% | +0.5% |
| Sep 22, 2026 | Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026 | +4.2% | -0.0% |
| Sep 11, 2026 | FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S. | +3.7% | +0.9% |
Quantisnow market dataNASDAQ
PHAR
Pharming Group N.V. ADS each representing 10
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for PHAR
Full PHAR profile on Quantisnow Follow PHAR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time